A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer

被引：0
|
作者：
Yoshino, T. [1 ]
Siena, S. [2 ]
Dalal, R. [3 ]
Okuda, Y. [4 ]
Yamamoto, E. [5 ]
Grothey, A. [6 ]
机构：
[1] Natl Canc Ctr Hosp East, Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[2] Univ Milan, Niguarda Canc Ctr, Milan, Italy
[3] Daiichi Sankyo Inc, Med, Basking Ridge, NJ USA
[4] Daiichi Sankyo Co Ltd, Biostat & Data Management Dept, Chuo Ku, Tokyo, Japan
[5] Daiichi Sankyo Co Ltd, Clin Dev, Chuo Ku, Tokyo, Japan
[6] Mayo Clin, Canc Ctr, Dept Med Oncol, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146TiP
引用
收藏
页码：45 / 45
页数：1
相关论文
共 50 条
  • [1] A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Trial in progress
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer
    Shitara, K.
    Bang, Y-J.
    Sakai, D.
    Yasui, H.
    Kawaguchi, Y.
    Sugihara, M.
    Saito, K.
    Dalal, R.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 65 - 65
  • [3] Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Yoshino, T.
    Iwata, H.
    Tamura, K.
    Takahashi, S.
    Redfern, C.
    Modi, S.
    Doi, T.
    Kawakami, H.
    Taniguchi, H.
    Takashima, A.
    Yamaguchi, K.
    Fisher, J.
    Li, B.
    Saito, K.
    Fujisaki, Y.
    Sugihara, M.
    Tsurutani, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Sakai, Daisuke
    Yasui, Hisateru
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer
    Iwasa, Satoru
    Shitara, Kohei
    Takahashi, Shunji
    Park, Haeseong
    Kadowaki, Shigenori
    Modi, Shanu
    Nonagase, Yoshikane
    Tamura, Kenji
    Yamaguchi, Kensei
    Muro, Kei
    Tsurutani, Junji
    Shahidi, Javad
    Lee, Caleb C.
    Sugihara, Masahiro
    Kawaguchi, Yoshinori
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Trastuzumab deruxtecan for HER2-expressing metastatic colorectal cancer
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (07): : S31 - S31
  • [7] A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS 8201a) in subjects with HER2-expressing gastric cancer.
    Shitara, Kohei
    Bang, Yung-Jue
    Chung, Hyun Cheol
    Yabusaki, Hiroshi
    Iwasa, Satoru
    Sakai, Daisuke
    Muro, Kei
    Sugimoto, Naotoshi
    Yasui, Hisateru
    Gamoh, Makio
    Murakawa, Yasuko
    Negoro, Yuji
    Nishina, Tomohiro
    Hosaka, Hisashi
    Omuro, Yasushi
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [8] Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study
    Modi, S.
    Tsurutani, J.
    Tamura, K.
    Park, H.
    Sagara, Y.
    Murthy, R.
    Iwata, H.
    Krop, I. E.
    Doi, T.
    Redfern, C.
    Moreno-Aspitia, A.
    Redman, R.
    Lee, C.
    Sugihara, M.
    Fujisaki, Y.
    Takahashi, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer
    Yamashita, Toshinari
    Shimomura, Akihiko
    Takano, Toshimi
    Sagara, Yasuaki
    Watanabe, Junichiro
    Tokunaga, Eriko
    Kikumori, Kunika
    Kamiyama, Emi
    Kamio, Takahiro
    Nakamura, Ryo
    Shinkai, Tetsu
    Takahashi, Shunji
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
    Hamilton, Erika
    Galsky, Matthew D.
    Ochsenreither, Sebastian
    Del Conte, Gianluca
    Martin, Miguel
    De Miguel, Maria Jose
    Yu, Evan Y.
    Williams, Anja
    Gion, Maria
    Tan, Antoinette R.
    Agrawal, Laila
    Rutten, Annemie
    Machiels, Jean-Pascal
    Cresta, Sara
    Debruyne, Philip R.
    Hennequin, Audrey
    Moreno, Victor
    Minchom, Anna
    Valdes-Albini, Frances
    Petrylak, Daniel
    Li, Li
    Tsuchihashi, Zenta
    Suto, Fumitaka
    Cheng, Fu-Chih
    Kandil, Maha
    Barrios, Daniel
    Hurvitz, Sara
    CLINICAL CANCER RESEARCH, 2024, 30 (24) : 5548 - 5558
12345